$GOVX
GeoVax Labs, Inc.

2018 Q2 Form 10-Q Financial Statement

#000143774918014749 Filed on August 07, 2018

View on sec.gov

Income Statement

Concept 2018 Q2 2017 Q2
Revenue $93.27K $352.1K
YoY Change -73.51% 111.77%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $360.0K $350.0K
YoY Change 2.86% 2.94%
% of Gross Profit
Research & Development $372.2K $518.1K
YoY Change -28.16% 30.31%
% of Gross Profit
Depreciation & Amortization $10.00K $0.00
YoY Change
% of Gross Profit
Operating Expenses $731.4K $870.3K
YoY Change -15.96% 17.23%
Operating Profit -$638.1K -$518.2K
YoY Change 23.16% -10.06%
Interest Expense $625.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $1.091K $1.271K
YoY Change -14.16%
Pretax Income -$640.0K -$520.0K
YoY Change 23.08% -10.34%
Income Tax
% Of Pretax Income
Net Earnings -$637.0K -$516.9K
YoY Change 23.25% -10.24%
Net Earnings / Revenue -683.05% -146.78%
Basic Earnings Per Share
Diluted Earnings Per Share -$82.09B -$172.9B
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q2 2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $190.0K $820.0K
YoY Change -76.83% 272.73%
Cash & Equivalents $191.0K $822.6K
Short-Term Investments
Other Short-Term Assets $150.0K $30.00K
YoY Change 400.0% -25.0%
Inventory
Prepaid Expenses
Receivables $0.00 $80.00K
Other Receivables $0.00 $0.00
Total Short-Term Assets $339.1K $933.6K
YoY Change -63.67% 260.71%
LONG-TERM ASSETS
Property, Plant & Equipment $21.22K $45.38K
YoY Change -53.24% -34.44%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $10.00K $10.00K
YoY Change 0.0% 0.0%
Total Long-Term Assets $32.23K $56.39K
YoY Change -42.84% -29.71%
TOTAL ASSETS
Total Short-Term Assets $339.1K $933.6K
Total Long-Term Assets $32.23K $56.39K
Total Assets $371.4K $990.0K
YoY Change -62.49% 191.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $66.03K $152.0K
YoY Change -56.54% 288.89%
Accrued Expenses $998.1K $499.6K
YoY Change 99.76% 453.65%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $1.068M $651.6K
YoY Change 63.95% 261.6%
LONG-TERM LIABILITIES
Long-Term Debt $50.00K $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $50.00K $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.068M $651.6K
Total Long-Term Liabilities $50.00K $0.00
Total Liabilities $1.114M $650.0K
YoY Change 71.4% 261.11%
SHAREHOLDERS EQUITY
Retained Earnings -$39.18M -$36.81M
YoY Change 6.42% 7.18%
Common Stock $36.72M $35.17M
YoY Change 4.41% 5.03%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$742.7K $338.4K
YoY Change
Total Liabilities & Shareholders Equity $371.4K $990.0K
YoY Change -62.49% 191.99%

Cashflow Statement

Concept 2018 Q2 2017 Q2
OPERATING ACTIVITIES
Net Income -$637.0K -$516.9K
YoY Change 23.25% -10.24%
Depreciation, Depletion And Amortization $10.00K $0.00
YoY Change
Cash From Operating Activities -$380.0K -$430.0K
YoY Change -11.63% -20.37%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 1.080M
YoY Change -100.0% 1100.0%
NET CHANGE
Cash From Operating Activities -380.0K -430.0K
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 0.000 1.080M
Net Change In Cash -380.0K 650.0K
YoY Change -158.46% -244.44%
FREE CASH FLOW
Cash From Operating Activities -$380.0K -$430.0K
Capital Expenditures $0.00 $0.00
Free Cash Flow -$380.0K -$430.0K
YoY Change -11.63% -20.37%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q2 govx Accrued Directors Fees Current
AccruedDirectorsFeesCurrent
238669
CY2017Q4 govx Accrued Directors Fees Current
AccruedDirectorsFeesCurrent
182620
govx Class Of Warrant Or Right Exchanged During Period Exercise Price
ClassOfWarrantOrRightExchangedDuringPeriodExercisePrice
govx Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
CY2017Q2 govx Revenue From Collaboration
RevenueFromCollaboration
95000
govx Revenue From Collaboration
RevenueFromCollaboration
95000
CY2018Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
66032
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
77581
CY2018Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
998062
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
733711
CY2018Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
710643
CY2017Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
532615
CY2018Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
653375
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
643445
CY2018Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
36558210
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
35589911
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
497098
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
303972
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
199900000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
285500000
CY2018Q2 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
8400
CY2018Q2 us-gaap Assets
Assets
371380
CY2017Q4 us-gaap Assets
Assets
490235
CY2018Q2 us-gaap Assets Current
AssetsCurrent
339149
CY2017Q4 us-gaap Assets Current
AssetsCurrent
448074
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
811292
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
9930
us-gaap Basis Of Accounting
BasisOfAccounting
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.</div>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Basis of Presentation</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The accompanying condensed consolidated financial statements at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018 </div>and for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-month and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div>-month periods ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> are unaudited, but include all adjustments, consisting of normal recurring entries, which we believe to be necessary for a fair presentation of the dates and periods presented. Interim results are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> necessarily indicative of results for a full year. The financial statements should be read in conjunction with our audited consolidated financial statements included in our Annual Report on Form <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>-K for the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2017. </div>We expect our operating results to fluctuate for the foreseeable future; therefore, period-to-period comparisons should <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> be relied upon as predictive of the results in future periods.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Our financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">twelve</div>-month period following the date of the financial statements. We are devoting substantially all of our present efforts to research and development of our vaccine candidates. We have funded our activities to date from government grants and clinical trial assistance, and from sales of our equity securities. We will continue to require substantial funds to continue these activities.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We believe that our existing cash resources and government funding commitments will be sufficient to continue our planned operations to mid-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> September 2018. </div>Due to our history of operating losses and our continuing need for capital to conduct our research and development activities, there is substantial doubt concerning our ability to operate as a going concern beyond that date. We are currently exploring sources of capital through additional government grants and contracts. We also intend to secure additional funds through sales of our equity securities or by other means. Management believes that we will be successful in securing the additional capital required to continue the Company&#x2019;s planned operations, but that our plans do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> fully alleviate the substantial doubt about the Company&#x2019;s ability to operate as a going concern. Additional funding <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> be available on favorable terms or at all. If we fail to obtain additional capital when needed, we will be required to delay, scale back, or eliminate some or all of our research and development programs as well as reduce our general and administrative expenses.</div></div>
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
312727
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
454030
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
190969
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
822597
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-121758
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
368567
CY2018Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
178571
CY2018Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0
CY2018Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.042
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
600000000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
600000000
CY2018Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
164736810
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
106736810
CY2018Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
164736810
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
106736810
CY2018Q2 us-gaap Common Stock Value
CommonStockValue
164737
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
106737
us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
795
us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
58
us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
53000000
us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
3862000
CY2018Q2 us-gaap Deposits Assets
DepositsAssets
11010
CY2017Q4 us-gaap Deposits Assets
DepositsAssets
11010
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
13796
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
359197
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
352191
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
716425
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
644858
CY2018Q2 us-gaap Grants Receivable
GrantsReceivable
CY2017Q4 us-gaap Grants Receivable
GrantsReceivable
59758
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
252802
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
281745
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-41695
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-30027
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-59758
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
50698
CY2018Q2 us-gaap Interest Expense
InterestExpense
625
CY2017Q2 us-gaap Interest Expense
InterestExpense
us-gaap Interest Expense
InterestExpense
833
us-gaap Interest Expense
InterestExpense
CY2018Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
1716
CY2017Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
1271
us-gaap Investment Income Interest
InvestmentIncomeInterest
3034
us-gaap Investment Income Interest
InvestmentIncomeInterest
1657
CY2018Q2 us-gaap Liabilities
Liabilities
1114094
CY2017Q4 us-gaap Liabilities
Liabilities
811292
CY2018Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
371380
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
490235
CY2018Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1068262
CY2018Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
45832
CY2017Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
us-gaap Net Income Loss
NetIncomeLoss
-1258856
us-gaap Net Income Loss
NetIncomeLoss
-1065222
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-637043
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4350
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-761758
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-761250
us-gaap Nature Of Operations
NatureOfOperations
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.</div>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Description of Business </div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">GeoVax Labs, Inc. (&#x201c;GeoVax&#x201d; or the &#x201c;Company&#x201d;), is a clinical-stage biotechnology company developing human vaccines using our novel vaccine platform. Our current development programs are focused on preventive vaccines against Human Immunodeficiency Virus (HIV), Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, Lassa), and malaria, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. We believe our technology and vaccine development expertise are well-suited for a variety of human infectious diseases and we intend to pursue further expansion of our product pipeline.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Certain of our vaccine development activities have been, and continue to be, financially supported by the U.S. government. This support has been both in the form of research grants and contracts awarded directly to us, as well as indirect support for the conduct of preclinical animal studies and human clinical trials.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We operate in a highly regulated and competitive environment. The manufacturing and marketing of pharmaceutical products require approval from, and are subject to, ongoing oversight by the Food and Drug Administration (FDA) in the United States, by the European Medicines Agency (EMA) in the European Union, and by comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>take many years and often involves expenditure of substantial resources. Our goal is to build a profitable company by generating income from products we develop and commercialize, either alone or with <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> or more potential strategic partners.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">GeoVax is incorporated under the laws of the State of Delaware and our principal offices are located in Smyrna, Georgia (metropolitan Atlanta area).</div></div>
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
640000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1134167
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-516881
CY2018Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1091
CY2017Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1271
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2201
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1657
CY2018Q2 us-gaap Notes Payable Current
NotesPayableCurrent
4168
CY2017Q4 us-gaap Notes Payable Current
NotesPayableCurrent
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
731399
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
870289
us-gaap Operating Expenses
OperatingExpenses
1575621
us-gaap Operating Expenses
OperatingExpenses
1714751
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-638134
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-518152
us-gaap Operating Income Loss
OperatingIncomeLoss
-1261057
us-gaap Operating Income Loss
OperatingIncomeLoss
-1066879
CY2018Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
78273
CY2018Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
48750
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
18476
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4350
CY2018Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2018Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
148180
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
75589
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
154167
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
590000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
980000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
50000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
31151
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
372202
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
518098
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
859196
CY2018Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
674596
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
674596
CY2018Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21221
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1069893
CY2018Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-39175646
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-37916790
CY2018Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
93265
CY2017Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
352137
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
314564
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
647872
us-gaap Share Based Compensation
ShareBasedCompensation
132913
us-gaap Share Based Compensation
ShareBasedCompensation
29102
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1890618
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.71
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
138000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
3.01
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7024275
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6886275
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.29
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.24
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
5000000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
-742714
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-321057
CY2018Q2 us-gaap Unrecorded Unconditional Purchase Obligation Balance Sheet Amount
UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount
248000
CY2018Q1 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
155209337
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
59791475
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
139775484
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
57583491

Files In Submission

Name View Source Status
0001437749-18-014749-index-headers.html Edgar Link pending
0001437749-18-014749-index.html Edgar Link pending
0001437749-18-014749.txt Edgar Link pending
0001437749-18-014749-xbrl.zip Edgar Link pending
ex_119432.htm Edgar Link pending
ex_119433.htm Edgar Link pending
ex_119434.htm Edgar Link pending
ex_119435.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
govx-20180630.xml Edgar Link completed
govx-20180630.xsd Edgar Link pending
govx-20180630_cal.xml Edgar Link unprocessable
govx-20180630_def.xml Edgar Link unprocessable
govx-20180630_lab.xml Edgar Link unprocessable
govx-20180630_pre.xml Edgar Link unprocessable
govx20180630_10q.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending